Bausch Health Companies Inc. Stock 12‑Month Price Target Raised to $7.72, Implies 12% Upside
Analysts raised Bausch Health's 12-month price target to $7.72, up from $7.54, implying 12% upside. The consensus rating remains 'Hold' with 1 Buy, 5 Holds, and 0 Sells. The forecasts range from $6.51 to $10.03 per share, according to 5 analysts.
How this was made

The 30-second read
Why it matters
Analyst upgrades typically generate short‑term buying interest, but the magnitude is modest given the small absolute price level.
Market read
The update offers a small upside catalyst for BHC but is unlikely to move broader markets.
What to watch
Potential downside from pending regulatory or litigation risks not reflected in the new target.
Background
Bausch Health Companies Inc. (NYSE:BHC) is a specialty pharmaceutical firm. The article reports a fresh analyst consensus price‑target increase.
Ticker impact
Analyst consensus price target raised to $7.72, implying ~12% upside versus the Oct. 28 close.
likely modest upside as the market incorporates the higher target
Price‑target upgrades are a forward‑looking signal; the change is modest and reflects incremental optimism.
Market effects
Minor impact on the healthcare sector as Bausch Health is a small‑cap pharma player.
Limited to North American markets where the stock trades.
Low; the story does not affect broader market indices.
Counterpoint
The target raise may be premature if underlying earnings guidance remains unchanged.
Key entities
- companyBausch Health Companies Inc.
Specialty pharma company whose price target was raised.


